<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02245620</url>
  </required_header>
  <id_info>
    <org_study_id>SPITM-201</org_study_id>
    <nct_id>NCT02245620</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly</brief_title>
  <acronym>MOTION</acronym>
  <official_title>A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Impact of a Single Intravenous Dose of MTP-131 (Bendavia™) on Skeletal Muscle Function in the Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stealth BioTherapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stealth BioTherapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a Phase 2, randomized, double-blind, placebo-controlled study, enrolling 41 elderly
      subjects with previous evidence of mitochondrial dysfunction to evaluate whether the
      administration of MTP-131 (elamipretide) will change either hand skeletal muscle energetics
      or muscle performance in age-related skeletal muscle mitochondrial dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase 2, randomized, double-blind, placebo-controlled study, enrolling 41 elderly
      subjects with previous evidence of mitochondrial dysfunction to evaluate whether the
      administration of MTP-131 (elamipretide) will change either hand skeletal muscle energetics
      or muscle performance in age-related skeletal muscle mitochondrial dysfunction.

      Subjects were randomized 1:1 to receive either elamipretide at 0.25 mg/kg/hr intravenously at
      a rate of 60 mL/hr for 2 hours, or placebo (lyophilized excipients without elamipretide)
      intravenously at a rate of 60 mL/hr for 2 hours. Each treatment group went through three
      distinct periods: Screening (up to 28 days), Treatment (1day), and Observation (7 days).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2015</start_date>
  <completion_date type="Actual">July 6, 2016</completion_date>
  <primary_completion_date type="Actual">July 6, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in ATPmax (Maximal ATP Synthetic Rate)</measure>
    <time_frame>From Baseline, Day 1 Hour 2 (2 hours after the start of infusion, or end of infusion) and Day 7</time_frame>
    <description>Maximal ATP synthetic rate (phosphorylation capacity per unit muscle volume) as determined by a muscle fatigue test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Phosphate/Oxygen (P/O) Ratio</measure>
    <time_frame>From Baseline, Day 1 Hour 2 (2 hours after the start of infusion, or end of infusion) and Day 7</time_frame>
    <description>As a measure of mitochondrial hand skeletal muscle energetics, mitochondrial coupling, or Phosphate/Oxygen ratio (P/O) was assessed at Baseline, Day 1 Hour 2, and Day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Nicotine Adenine Dinucleotide (NAD)</measure>
    <time_frame>From Baseline, Day 1 Hour 2 (2 hours after the start of infusion, or end of infusion) and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Muscle Force-Time-Integral (FTI)</measure>
    <time_frame>From Baseline to Day 1 Hour 2, Day 3, and Day 7</time_frame>
    <description>Muscle Force-Time-Integral was measured as mean change from baseline at Day 1 Hour 2, Day 3, and Day 7.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Skeletal Muscle Mitochondrial Dysfunction in the Elderly</condition>
  <arm_group>
    <arm_group_label>Elamipretide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elamipretide given as an intravenous infusion of 0.25 mg/kg/hr at a rate of 60 mL/hr for 2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (lyophilized excipients without elamipretide) given as an intravenous infusion at a rate of 60 mL/hr for 2 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elamipretide</intervention_name>
    <description>Elamipretide 0.25 mg/kg/hour administered as an intravenous infusion at the rate of 60 mL/hour for 2 hours</description>
    <arm_group_label>Elamipretide</arm_group_label>
    <other_name>MTP-131</other_name>
    <other_name>Bendavia™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>elamipretide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Are male and female adults aged ≥60 and ≤85 years

          2. Female subjects must be post-menopausal

          3. Have in vivo phosphorus-31 (31P) Magnetic Resonance Spectroscopy (MRS) and (Optical
             Spectra Scan (OPS) determined maximum adenosine triphosphate synthetic rate (ATPmax) &lt;
             0.70 milliMol/second (mM/sec)

          4. Have in vivo 31P MRS and OPS determined P/O (Phosphate/Oxygen ratio) &lt; 1.9

          5. Are ambulatory and able to perform activities of daily living without assistance

          6. Had sufficient venous access for study drug administration and clinical testing.

          7. Could speak and read English fluently.

          8. Provided informed consent.

        Exclusion Criteria:

          1. Had significant disease(s) or condition(s) which, in the opinion of the Investigator,
             may have put the subject at risk because of their participation in the study or may
             have influenced either the results of the study or the subject's ability to
             participate in the study.

          2. Had a history of rhabdomyolysis.

          3. Had been hospitalized within 3 months prior to Screening for major atherosclerotic
             events (e.g., myocardial infarction, target-vessel revascularization, coronary bypass
             surgery or stroke) or other major medical condition (as deemed by the Primary
             Investigator).

          4. Had any metal implants that could not be removed from the body that in the opinion of
             the Investigator were a contra-indication for undergoing the MRS procedure or any
             other protocol-related procedure.

          5. Had an implanted cardiac pacemaker or other implanted cardiac device.

          6. Had a serum sodium level &lt;136 milliequivalents per litre (mEq/L) at Screening or
             Pre-infusion.

          7. Had a hemoglobin level &lt;12 g/dL at Screening or Pre-infusion.

          8. Had chronic, uncontrolled hypertension as judged by the Investigator (e.g., Baseline
             systolic blood pressure [SBP] &gt;140 mm Hg, diastolic blood pressure [DBP] &gt; 90 mm Hg)
             or a SBP &gt;150 mm Hg or DBP &gt;95 mm Hg at the time of Screening or Baseline (if the
             initial blood pressure [BP] reading was above these values, the reading may have been
             repeated one time within 20 minutes of the initial reading).

          9. Had a body mass index (BMI) of &lt;16 or &gt;35 kg/m2.

         10. Had a creatinine clearance &lt;45 mL/min as calculated by the Cockcroft Gault equation.

         11. Had a 12-lead electrocardiogram (ECG) demonstrating severe bradycardia (heart rate &lt;
             40 bpm) or average corrected QC interval (QTc) &gt;450 ms for males and &gt; 470 ms for
             females, and in the opinion of the Investigator was clinically significant. (If on the
             initial ECG, QTc exceeded 450 ms for males or 470 ms for females, the ECG was to be
             repeated 2 more times and the average of the 3 QTc values was to be used to determine
             the subject's eligibility).

         12. Had a neurologic disorder that in the opinion of the Investigator was a
             contra-indication for enrollment into the study.

         13. Had any symptoms consistent with or a current diagnosis of peripheral neuropathy, such
             as numbness, tingling, pain, or altered sensation of hands or feet.

         14. Had an active, systemic autoimmune disease other than autoimmune thyroid disease
             (e.g., diabetes, lupus, rheumatoid arthritis) that currently required treatment or was
             likely to require treatment during the study.

         15. Subject's right hand had a history of mobility impairment, fractures, arthritis, hand
             surgery, muscle disease or other injury that may interfere with any study procedure.

         16. Had any symptoms consistent with or a current diagnosis of claustrophobia.

         17. Had a history of cancer, unless subject had documentation of completed curative
             treatment.

         18. Had a history of or risk factors (e.g., significant family history, concomitant
             medical condition) for deep vein thrombosis or pulmonary embolism.

         19. Had a history of serious mental illness as judged by the Investigator.

         20. Had a body temperature &gt; 37.5°C at the time of planned dosing.

         21. Subjects who in the opinion of the Investigator abused alcohol or drugs.

         22. Had donated or received blood or blood products within the past 30 days.

         23. Investigator site personnel directly affiliated with this study and/or their immediate
             families. Immediate family was defined as a spouse, parent, child, or sibling, whether
             biological or legally adopted.

         24. Sponsor employees and/or their immediate families. Immediate family was defined as a
             spouse, parent, child, or sibling, whether biological or legally adopted.

         25. Were currently enrolled in a clinical study involving an investigational product or
             non-approved use of a drug or device or concurrently enrolled in any other type of
             medical research judged to be scientifically or medically incompatible with this
             study.

         26. Had participated, within the last 30 days, in a clinical study involving an
             investigational product. If the previous investigational product had a long half-life,
             3 months or 5 half-lives (whichever was longer) should have passed.

         27. Had previously been randomized into any study investigating elamipretide or been
             exposed to elamipretide for any reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Carr</last_name>
    <role>Study Director</role>
    <affiliation>Stealth BioTherapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 17, 2014</study_first_submitted>
  <study_first_submitted_qc>September 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2014</study_first_posted>
  <results_first_submitted>May 31, 2020</results_first_submitted>
  <results_first_submitted_qc>June 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 23, 2020</results_first_posted>
  <last_update_submitted>June 20, 2020</last_update_submitted>
  <last_update_submitted_qc>June 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skeletal muscle dysfunction, MTP-131, Bendavia™</keyword>
  <keyword>elamipretide</keyword>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>2 subjects discontinued prematurely as per Investigator’s discretion. These 2 subjects (Subject 001019 [Elamipretide group] and Subject 001063 [Placebo group]) were discontinued after randomization but prior to receiving study treatment; both were not treated due to their pre-infusion sodium levels meeting Exclusion Criteria 6.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Elamipretide</title>
          <description>Elamipretide administered as an intravenous infusion of 0.25 mg/kg/hr at a rate of 60 mL/hr for 2 hours.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MTP-131 (Bendavia™)</title>
          <description>MTP-131 (Bendavia™) administered as an intravenous infusion of 0.25 mg/kg/hr at a rate of 60 mL/hr for 2 hours.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.9" spread="3.35"/>
                    <measurement group_id="B2" value="69.0" spread="3.96"/>
                    <measurement group_id="B3" value="68.5" spread="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass index</title>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.5" spread="4.27"/>
                    <measurement group_id="B2" value="26.1" spread="2.82"/>
                    <measurement group_id="B3" value="26.3" spread="3.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in ATPmax (Maximal ATP Synthetic Rate)</title>
        <description>Maximal ATP synthetic rate (phosphorylation capacity per unit muscle volume) as determined by a muscle fatigue test.</description>
        <time_frame>From Baseline, Day 1 Hour 2 (2 hours after the start of infusion, or end of infusion) and Day 7</time_frame>
        <population>All participants for whom Maximal ATP synthetic rate was measured at baseline and Day 1 Hour 2, and Day 7</population>
        <group_list>
          <group group_id="O1">
            <title>MTP-131 (Bendavia™)</title>
            <description>MTP-131 (Bendavia™) administered as an intravenous infusion of 0.25 mg/kg/hr at a rate of 60 mL/hr for 2 hours.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ATPmax (Maximal ATP Synthetic Rate)</title>
          <description>Maximal ATP synthetic rate (phosphorylation capacity per unit muscle volume) as determined by a muscle fatigue test.</description>
          <population>All participants for whom Maximal ATP synthetic rate was measured at baseline and Day 1 Hour 2, and Day 7</population>
          <units>mM/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 Hour 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.196"/>
                    <measurement group_id="O2" value="0.12" spread="0.244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.142"/>
                    <measurement group_id="O2" value="0.06" spread="0.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Phosphate/Oxygen (P/O) Ratio</title>
        <description>As a measure of mitochondrial hand skeletal muscle energetics, mitochondrial coupling, or Phosphate/Oxygen ratio (P/O) was assessed at Baseline, Day 1 Hour 2, and Day 7.</description>
        <time_frame>From Baseline, Day 1 Hour 2 (2 hours after the start of infusion, or end of infusion) and Day 7</time_frame>
        <population>All participants for whom Phosphate/Oxygen (P/O) ratio was measured at baseline and Day 1 Hour 2, and Day 7</population>
        <group_list>
          <group group_id="O1">
            <title>MTP-131 (Bendavia™)</title>
            <description>MTP-131 (Bendavia™) administered as an intravenous infusion of 0.25 mg/kg/hr at a rate of 60 mL/hr for 2 hours.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Phosphate/Oxygen (P/O) Ratio</title>
          <description>As a measure of mitochondrial hand skeletal muscle energetics, mitochondrial coupling, or Phosphate/Oxygen ratio (P/O) was assessed at Baseline, Day 1 Hour 2, and Day 7.</description>
          <population>All participants for whom Phosphate/Oxygen (P/O) ratio was measured at baseline and Day 1 Hour 2, and Day 7</population>
          <units>ratio of phosphate to oxygen</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 Hour 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.679"/>
                    <measurement group_id="O2" value="0.26" spread="0.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.473"/>
                    <measurement group_id="O2" value="0.51" spread="0.788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Nicotine Adenine Dinucleotide (NAD)</title>
        <time_frame>From Baseline, Day 1 Hour 2 (2 hours after the start of infusion, or end of infusion) and Day 7</time_frame>
        <population>All participants for whom Nicotine Adenine Dinucleotide (NAD) was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>MTP-131 (Bendavia™)</title>
            <description>MTP-131 (Bendavia™) administered as an intravenous infusion of 0.25 mg/kg/hr at a rate of 60 mL/hr for 2 hours.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Nicotine Adenine Dinucleotide (NAD)</title>
          <population>All participants for whom Nicotine Adenine Dinucleotide (NAD) was measured.</population>
          <units>millimolar</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 Hour 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.169"/>
                    <measurement group_id="O2" value="0.01" spread="0.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.215"/>
                    <measurement group_id="O2" value="0.09" spread="0.263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Muscle Force-Time-Integral (FTI)</title>
        <description>Muscle Force-Time-Integral was measured as mean change from baseline at Day 1 Hour 2, Day 3, and Day 7.</description>
        <time_frame>From Baseline to Day 1 Hour 2, Day 3, and Day 7</time_frame>
        <population>All participants for whom Muscle Force-Time-Integral (FTI) was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>MTP-131 (Bendavia™)</title>
            <description>MTP-131 (Bendavia™) administered as an intravenous infusion of 0.25 mg/kg/hr at a rate of 60 mL/hr for 2 hours.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Muscle Force-Time-Integral (FTI)</title>
          <description>Muscle Force-Time-Integral was measured as mean change from baseline at Day 1 Hour 2, Day 3, and Day 7.</description>
          <population>All participants for whom Muscle Force-Time-Integral (FTI) was measured.</population>
          <units>Newton/second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 Hour 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.882"/>
                    <measurement group_id="O2" value="0.10" spread="0.728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="1.036"/>
                    <measurement group_id="O2" value="0.24" spread="0.948"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="1.485"/>
                    <measurement group_id="O2" value="0.44" spread="1.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Elamipretide</title>
          <description>Elamipretide given as an intravenous infusion of 0.25 mg/kg/hr at a rate of 60 mL/hr for 2 hours.
Elamipretide: Elamipretide 0.25 mg/kg/hour administered as an intravenous infusion at the rate of 60 mL/hour for 2 hours</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo (lyophilized excipients without elamipretide) given as an intravenous infusion at a rate of 60 mL/hr for 2 hours.
Placebo: Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 19.0">Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 19.0">Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jim Carr, Pharm.D. Chief Clinical Development Officer</name_or_title>
      <organization>Stealth BioTherapeutics, Inc</organization>
      <phone>1-617-600-6888</phone>
      <email>jim.carr@stealthbt.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

